Rankings
▼
Calendar
FHTX Q4 2023 Earnings — Foghorn Therapeutics Inc. Revenue & Financial Results | Market Cap Arena
FHTX
Foghorn Therapeutics Inc.
$330M
Q4 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$6M
+37.9% YoY
Gross Profit
$5M
85.2% margin
Operating Income
-$25M
-441.3% margin
Net Income
-$24M
-417.9% margin
EPS (Diluted)
$-0.57
QoQ Revenue Growth
-67.0%
Cash Flow
Operating Cash Flow
-$28M
Free Cash Flow
-$28M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$286M
Total Liabilities
$363M
Stockholders' Equity
-$77M
Cash & Equivalents
$80M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$6M
$4M
+37.9%
Gross Profit
$5M
-$24M
+120.5%
Operating Income
-$25M
-$32M
+20.2%
Net Income
-$24M
-$29M
+16.5%
← FY 2023
All Quarters
Q1 2024 →